Tan Tock Seng Hospital
ttsh.com.sgTotal trials
102
Active
27
Phase 3
7
Total enrollment
51,044
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oral fluoroquinolones (most commonly, ciprofloxacin) or oral trimethoprim-sulfamethoxazole | — | — | — | — | — | 1 | |
| Standard of care intravenous antibiotics | — | — | — | — | — | 1 |
Next readouts
- 2026-05
Top conditions
- Stroke27
- Knee Osteoarthritis5
- Traumatic Brain Injury3
- Acquired Brain Injury3
- Osteoarthritis, Knee2
- Amputation2
- Parkinson Disease2
- Fatigue2
Frequently asked questions about Tan Tock Seng Hospital
- How many clinical trials does Tan Tock Seng Hospital have on ClinicalTrials.gov?
- Tan Tock Seng Hospital is listed as the lead sponsor on 102 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Tan Tock Seng Hospital's trials are in Phase 3?
- 7 of Tan Tock Seng Hospital's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Tan Tock Seng Hospital focus on?
- Tan Tock Seng Hospital's most-studied conditions on ClinicalTrials.gov are Stroke, Knee Osteoarthritis, Traumatic Brain Injury, Acquired Brain Injury, Osteoarthritis, Knee.
- When are Tan Tock Seng Hospital's next clinical trial readouts?
- Tan Tock Seng Hospital has 1 upcoming primary-completion readout tracked here; the soonest is “Early Oral Switch for Uncomplicated Gram-negative Bacteraemia”, expected around 2026-05.